Archive for September 4, 2019
Largest Real-World Study of Immunotherapy Shows Men with Advanced Prostate Cancer with Low PSA had a Median Survival of Nearly Four Years after Treatment with PROVENGE® (sipuleucel-T)
– Data from Nearly 2,000 Patients Finds that Men Treated with PROVENGE when Baseline PSA was <5.27 ng/mL Lived 47.7 Months – – Findings Consistent with Pivotal IMPACT Trial – September 04, 2019 01:15 PM Eastern Daylight Time SEAL BEACH, Calif.–(BUSINESS WIRE)–Dendreon Pharmaceuticals, a commercial-stage biopharmaceutical company and pioneer in the development of immunotherapy, today…
Read MoreGeoVax Announces Publication of Lassa Fever Vaccine Study Results
100% Single-Dose Protection Observed in Lethal Challenge Model ATLANTA, GA, September 4, 2019 – GeoVax Labs, Inc. (OTCQB: GOVX), a biotechnology company developing human vaccines, today announced publication of its article entitled “A Single Dose of Modified Vaccinia Ankara Expressing Lassa Virus-like Particles Protects Mice from Lethal Intra-cerebral Virus Challenge.” The paper appears in the open…
Read MoreGeorgia Bio 2019 Legislative Session Recap
The 2019 Georgia 40-day legislative session concluded with Sine Die on Tuesday, April 2nd. This legislative session was characterized by new leadership in the Governor and Lt. Governor’s office, as well as 40 freshman legislators. Of the eight measures detailed below, there were two for which Georgia Bio actively advocated on behalf of our members…
Read More